/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
With biosimilars in the limelight, Kiran Mazumdar-Shaw’s company is poised to become one of India’s most important drug makers
Editor's note: Last October, in New York, Kiran Mazumdar-Shaw did what she does best—make the news. Talking at the UNAIDS Health Innovation Exchange held at the United Nations General Assembly, the founder of Biocon Ltd made an offer to make available human insulin at $0.10 per day to low- and middle-income countries, less than half the current prices. It was no mean offer, given that these countries accounted for 80% of the diabetes burden. Around the same time, in the Bengaluru headquarters of her company, managers were hard at work trying to find additional funds for several other things she had set in motion. As chairman and managing director, Mazumdar-Shaw was rapidly throwing more money into research, building new factories and hiring expatriate managers for her company. An idea to list a subsidiary overseas was on the table because she suspected that Indian investors wouldn’t value her firm appropriately. For those who have followed Mazumdar-Shaw over the last decade, the concurrent situation presents the dichotomy that has always surrounded her. Her business was the first to launch several copies of complex drugs …
With biosimilars in the limelight, Kiran Mazumdar-Shaw’s company is poised to become one of India’s most important drug makers
Editor's note: Last October, in New York, Kiran Mazumdar-Shaw did what she does best—make the news. Talking at the UNAIDS Health Innovation Exchange held at the United Nations General Assembly, the founder of Biocon Ltd made an offer to make available human insulin at $0.10 per day to low- and middle-income countries, less than half the current prices. It was no mean offer, given that these countries accounted for 80% of the diabetes burden. Around the same time, in the Bengaluru headquarters of her company, managers were hard at work trying to find additional funds for several other things she had set in motion. As chairman and managing director, Mazumdar-Shaw was rapidly throwing more money into research, building new factories and hiring expatriate managers for her company. An idea to list a subsidiary overseas was on the table because she suspected that Indian investors wouldn’t value her firm appropriately. For those who have followed Mazumdar-Shaw over the last decade, the concurrent situation presents the dichotomy that has always surrounded her. Her business was the first to launch several copies of complex drugs …
As the smart fan maker gears up for an IPO, prospective investors could do with some clarity on what the company’s next phase of growth will look like.
The stock market regulator is investigating a string of disappointing public listings. The idea is to send a message.
The quick-commerce startup weighs a valuation cut or finding alternative funding to stay afloat as investor appetite for loss-making businesses weakens.
As the smart fan maker gears up for an IPO, prospective investors could do with some clarity on what the company’s next phase of growth will look like.
The stock market regulator is investigating a string of disappointing public listings. The idea is to send a message.
The quick-commerce startup weighs a valuation cut or finding alternative funding to stay afloat as investor appetite for loss-making businesses weakens.
